Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

Clinical trial NCT00230763 · COMPLETED

Trial details

NCT number: NCT00230763
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Glaucoma, Primary Open Angle (POAG)Ocular Hypertension

Start date: 2005-09-01
Primary completion: 2007-10-01
Enrollment: 396

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.